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Abstract 
Synthetic compounds open up new avenues to interrogate and manipulate intracellular Ca2+ signalling 
pathways. These may ultimately lead to drug-like analogues to intervene in disease. Recent advances in 
chemical biology tools available to probe Ca2+ signalling are described, with a particular focus on those 
synthetic analogues from our group that have enhanced biological understanding or represent a step 
towards more drug-like molecules. Adenophostin (AdA) is the most potent known agonist at the inositol 
1,4,5-trisphosphate receptor (IP3R) and synthetic analogues provide a binding model for receptor activation 
and channel opening. 2-O-Modified inositol 1,4,5-trisphosphate derivatives that are partial agonists at the 
IP3R reveal key conformational changes of the receptor upon ligand binding. Biphenyl polyphosphates 
illustrate that simple non-inositol surrogates can be engineered to give prototype IP3R agonists or 
antagonists and act as templates for protein co-crystallization. Cyclic adenosine 5′-diphosphoribose (cADPR) 
can be selectively modified using total synthesis, generating chemically and biologically stable tools to 
investigate Ca2+ release via the ryanodine receptor (RyR) and to interfere with cADPR synthesis and 
degradation. The first neutral analogues with a synthetic pyrophosphate bioisostere surprisingly retain the 
ability to release Ca2+, suggesting a new route to membrane-permeant tools. Adenosine 5′-diphosphoribose 
(ADPR) activates the Ca2+-, Na+- and K+-permeable Transient Receptor Potential Melastatin 2 (TRPM2) cation 
channel. Synthetic ADPR analogues provide the first structure-activity relationship (SAR) for this emerging 
messenger, and the first functional antagonists. An analogue based on the nicotinic acid motif of nicotinic 
acid adenine dinucleotide phosphate (NAADP) antagonizes NAADP-mediated Ca2+ release in vitro and is 
effective in vivo against induced heart arrhythmia and autoimmune disease, illustrating the therapeutic 
potential of targeted small molecules. 
The molecules that stimulate Ca2+ release 
Ca2+ Regulates many cellular events and plays a key role in processes as diverse as cell division, muscle 
contraction, cell death and fertilization [1]. The spatial and temporal release of Ca2+ within the cell is tightly 
controlled by second messengers. In the thirty years since myo-inositol 1,4,5-trisphosphate (IP3) was shown 
to release Ca2+ from internal stores [2], the importance and complexity of IP3-regulated signalling pathways 
and the IP3 receptor (IP3R) have been revealed. More recently, three adenosine nucleotide-based second 
messengers cyclic adenosine 5′-diphosphoribose (cADPR), nicotinic acid adenine dinucleotide phosphate 
(NAADP) and adenosine 5′-diphosphoribose (ADPR) have been discovered [3]. In humans all three are 
formed from nicotinamide adenosine 5′-dinucleotide (NAD+) by the multifunctional ADPR-cyclase CD38 [4]. 
They mobilize Ca2+ using pathways unrelated to IP3. 
These four Ca2+-releasing second messengers are all highly specific ligands for their intramolecular ion 
channel target. Each has highly polar phosphate groups that are negatively charged at normal physiological 
pH [5] and likely correspond to positively charged or electron poor residues in their binding counterpart, an 
interaction often presumed to be critical for their activity. It is therefore a major challenge for synthetic 
chemists to design molecules that not only retain the specificity of the natural messengers, but also 
overcome the inherent barriers for studying biological processes in whole cells and organisms. Still more 
complex is the challenge to achieve specificity in translating molecules based upon such ubiquitous 
messengers into models of disease. 
2 
 
Small molecule design 
Currently, there are very few synthetic examples of neutral, active, drug-like molecules able to modulate 
one of these critical pathways. The non-competitive NAADP antagonist Ned-19 was identified by virtual 
screening [6] and is a valuable tool for biological studies [7]. Recently the specific cardiac ADPR cyclase 
inhibitors SAN2589 and SAN4825 were identified by high-throughput screening [8].  
Our design-based approach to chemical biology tools aims to address the following considerations: 
1) Membrane permeability to access intracellular receptors in whole cell systems: Multiple negatively 
charged phosphate groups give the natural messengers poor membrane permeability. The synthesis of 
caged analogues of NAADP, cADPR and IP3, where the phosphates are masked as ester derivatives or with 
photolabile groups, has addressed this to some extent [9-11]. The advantage of this strategy is that the exact 
natural ligand is released by intracellular esterases or upon irradiation. However, frequently the rate of 
release of the active compound is slow, particularly when multiple phosphates are involved, and is in 
competition with degradation to unwanted side products. Additionally, the modified analogues are not 
always chemically homogenous species. More recently, bioisosteric approaches [12] have successfully 
generated active neutral compounds making these an attractive alternative.  
2) The complexity of the natural Ca2+ signalling molecules: This frequently results in arduous multi-step 
synthetic routes and limits the scope, yield and number of analogues that can be prepared. Replication of 
biologically simple processes can be very difficult in a synthetic chemistry setting. This makes the search for 
useful biological tools demanding of time and resources. Simplified structures with shorter synthetic routes 
are appealing as they may be more quickly prepared, evaluated and optimized. 
3) The transient nature of the second messengers: This makes the natural compounds difficult to work with 
in biological studies as they may be unstable in aqueous solution or sensitive to physiological conditions (e.g. 
IP3 is a substrate for kinases and phosphatases, cADPR is readily hydrolyzed by CD38). By introducing 
chemical and biological stability, we can provide reliable tools that may be studied in isolation without 
interference from degradative pathways.  
4) The large size and hydrophilic nature: This is particularly true for the adenosine nucleotide messengers 
(e.g. NAADP has a molecular weight of 745). Generally, this does not translate well into a good drug and it 
exacerbates the difficulties of multistep, low yielding synthetic routes. Systematic studies to determine the 
structure-activity relationship (SAR) of the natural molecule can help to identify critical motifs and reduce 
the mass of a designed related ligand.  
5) Selectivity and specificity for the desired ion channel: This must be in preference to a number of similar 
ion channels that interact with highly similar species. Ligand design based on biological information, such as 
crystal structures where available, ensures that the affinity of a ligand is tuned to maximize interactions with 
its specific ion channel target. 
Agonists and antagonists for the IP3R 
Many analogues of IP3 have been synthesized to study SAR at the IP3R [13, 14]. In 1993, the glyconucleotide 
adenophostin A (AdA) was isolated from a culture broth of Penicillium brevicompactum [15]. It is an IP3R 
agonist with at least ten times greater potency and affinity than IP3. Its potency, the fact that it is not 
degraded by the enzymes that metabolize IP3, and the possibility of introducing synthetic modifications 
makes preparation of AdA analogues attractive, both as carbohydrate [16] and nucleotide derivatives [17]. 
Understanding interactions at the IP3R may ultimately lead to the rational design of potent ligands. 
A comparison of chemical structures suggests that the 3″,4″-bisphosphate of AdA may mimic the 4,5-
bisphosphate of IP3, and that perhaps the AdA 2′-phosphate group is better positioned to interact with the 
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IP3R binding site than the IP3 1-phosphate (Fig. 1A). However, synthesis of IP3 analogues in which the 1-
phosphate is positioned further from the ring (e.g. by two carbons) did not increase activity [18]. Preparation 
of an orthogonally protected disaccharide intermediate permitted introduction of modified bases and 
aromatic groups at C1′ to explore the effect of the adenine ring system on activity [19]. No analogue without 
an adenine base is more potent than IP3, suggesting that the adenine has a critical interaction with the IP3R. 
Modifications at N6 and C2 of the base generated additional SAR information about the shape and tolerance 
of the binding site (Fig. 1A).  
The bisphosphate analogues of AdA were synthesized via three bespoke routes to analyze the role of each 
phosphate group in binding to the IP3-binding core (IBC) of the IP3R. The IBC consists of α- and β-domains 
which operate like a clam, the closure of which activates channel opening [20]. The contrasting agonist 
activity of these analogues at the IP3R led to a proposed binding model in which any active analogue must 
engage both domains (Fig. 1B). Furthermore, the activity of 2′-dephospho-AdA (107 nM at IP3R1, cf. 23 nM 
for IP3) [20] suggests it is possible to design less polar IP3R agonists. At their simplest, future analogues might 
consist of a simple linker connecting groups to interact with each of the α- and β-domains. In combination 
with mutational analysis, a proposed important cation-π interaction between the adenine and Arg504 has 
been suggested to rationalize the enhanced potency of AdA (Fig. 1C). In support of this idea, mutation of this 
residue causes a much greater reduction in AdA affinity, compared to IP3 [21, 22]. 
Synthesis of 2-O-modified IP3 analogues (e.g. Fig. 1D) revealed key steps in IP3R activation. As partial agonists, 
they highlighted the role of a conformational change in the N-terminal domain to transmit information to 
the pore for channel opening [23]. Conjugation with fluorescein isothiocyanate (FITC) via an aminoethyl 
linker at the 2-position of IP3 gave the fluorescent analogue, FITC-IP3. This high affinity partial agonist was 
used to probe the thermodynamics of ligand binding using fluorescence polarization, establishing that the 
IBC alone is sufficient for the higher affinity binding of AdA, compared to IP3, but that the two ligands have 
different entropy and enthalpy contributions for binding [24].  
More recently, non-inositol based aromatic polyphosphates have provided a route to avoid some of the 
difficulties of IP3 and AdA synthesis, and show the potential to mimic interactions at the IP3R and elsewhere 
[25]. These simple achiral molecules are attractive for future analogue design, and often also remove the 
problem of differentiation between multiple hydroxyl groups and associated phosphate migration during 
synthesis. The IP3R antagonist biphenyl 2,3′,4,5′,6-pentakisphosphate was generated in only two steps (Fig. 
1E) [26]. Synthesis of biphenyl hexakisphosphate analogues illustrated that repositioning one phosphate 
group on the aromatic ring can induce an effective IP3R agonist/antagonist switch [27]. These compounds 
have also shown potential as templates for co-crystallization, facilitating the first high resolution structure 
of Src-homology 2 domain-containing inositol phosphatase 2 (SHIP2, Fig. 1F) [28]. Future iterations of such 
simple analogues will need to focus on reducing polarity to improve permeability and specificity over the 
related 5-phosphatases. However, the simplicity and versatility of the chemistry to access them implies that 
optimization should be straightforward. 
Probing Ca2+ release at the ryanodine receptor (RyR) with cADPR analogues 
cADPR Effects Ca2+ release directly or indirectly via the RyR [29], and analogues may provide agonist or 
antagonist tools to help elucidate the mechanism by which this occurs [30]. Since cADPR is readily hydrolyzed 
in both aqueous solution and under physiological conditions, stable analogues are highly desirable [31]. 
Initially, a chemoenzymatic route was employed to cyclize the respective NAD+ analogue using ADP-ribosyl 
cyclase from Aplysia californica. A 6-NH2  6=O substitution on the base gives a more chemically and 
biologically stable analogue, cIDPR, with an equivalent Ca2+-releasing ability in T-lymphocytes (Fig. 2B) [32], 
and this scaffold has been widely used in analogue design (Fig. 2A).  
 
To promote cyclization of the corresponding cIDPR precursor at N1, rather than N7, modification of the base 
at C8 is required [32]. This illustrates the limitations of using a chemoenzymatic route, but also led to the 
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discovery of the first membrane permeant cADPR agonist, 8-Br-cIDPR (Fig. 2C) [33]. Total synthesis routes 
have frequently required modification of the N1-ribose to improve analogue tractability and stability, for 
example in cADP-carbocyclic ribose [34], cIDPRE and cIDPDE [35, 36]. A recent review covers related 
analogues and their effect on Ca2+ activity in T-cells [37]. We have developed a total synthetic route to cIDPR 
analogues [38] that allows independent functionalization of each structural motif. Replacing the N9-ribose 
with a butyl chain improves the stability of the N9-link and should improve membrane permeability (Fig. 2A). 
These analogues inhibit hydrolysis of cADPR by CD38 and this may provide future opportunities for upstream 
Ca2+ modulation [39]. Furthermore, crystallization of 8-NH2-N9-butyl-cIDPR with CD38 catalytic domain 
revealed a potential mechanism for cADPR hydrolysis by the cyclase (Fig. 2D). Replacing the negatively 
charged pyrophosphate group is attractive in the quest for more drug-like, membrane permeant tools. The 
use of ‘click-chemistry’ generated the first neutral analogue of cADPR in which the phosphate is replaced 
with an uncharged bioisosteric 1,4-triazole (Fig. 2A) [40]. The surprising, albeit weak, activity of these first 
analogues in Ca2+-release (Fig. 2E) suggests that the cADPR receptor is a potentially druggable target. To 
assess the minimum structural requirement for activity, smaller fragment analogues (N1-inosine 
monophosphates, N1-IMP, Fig. 2A) were designed, based on the structures of CD38 co-crystallized with 
cIDPR analogues [41]. N1-IMP were accessed via acidic hydrolysis of the parent cyclic compound and are low 
M inhibitors of cADPR hydrolysis by CD38. They represent a promising lead to simpler low molecular weight 
inhibitors. 
 
Activation of the TRPM2 cation channel by ADPR 
ADPR activates Transient Receptor Potential Melastatin 2 (TRPM2), a Ca2+-permeable cation channel, and 
has only recently been considered a second messenger [42]. An important role for TRPM2 has been 
suggested in cells of the innate immune system [43]. The first SAR study of ADPR combined synthetic 
chemistry and chemoenzymatic methods to access analogues that were selectively modified in each of the 
four main structural motifs (Fig. 3A) [44]. 
Analogues were evaluated by whole cell patch clamp experiments using HEK293 cells transfected with 
TRPM2 (Fig. 3B). Introduction of a hydrophobic substituent at the adenine 8-position caused a switch in 
activity to generate the antagonist 8-phenyl-ADPR (Fig. 3C) and further improvement was achieved in 
combination with a 2′-deoxy modification on the adenosine ribose to generate the most potent TRPM2 
antagonist to date, 8-phenyl-2′-deoxy-ADPR (IC50 = 3 M). The former can be synthesized in only four steps 
from NAD+ by introduction of the 8-phenyl substituent to 8-Br-ADPR using Suzuki chemistry. 8-Phenyl-ADPR 
was shown to inhibit neutrophil migration, a downstream effect of TRPM2 activation (Fig. 3D) [44]. Weak 
antagonist activity was also seen when the pyrophosphate was substituted for a decorated sulfamate group, 
and this is a promising lead to more stable, less polar analogues of ADPR. However, useful analogues are still 
very much in their infancy for this application. 
Antagonists of the NAADP receptor 
NAADP is the most potent endogenous Ca2+-mobilizing compound known to date [45]. We synthesized 
NAADP via nicotinamide adenine dinucleotide phosphate (NADP) using a combined total synthesis and 
chemoenzymatic route [46]. NADP is inactive despite being structurally very similar to NAADP (Fig. 4A) [47]. 
Thus, the nicotinamide  nicotinic acid switch appeared to offer an opportunity for chemical biological 
intervention in NAADP-mediated Ca2+ signalling. Indeed, co-injection of nicotinic acid, but not nicotinamide, 
greatly reduced Ca2+ signalling induced by NAADP [48]. Furthermore, whereas NAADP is large in size and 
hydrophilic, nicotinic acid is a more attractive starting point for development of a membrane permeant small 
molecule. Cellular uptake of nicotinic acid itself is slow, so alkylation with 2-bromo-acetamides was used as 
a starting point to generate a library of alkylated derivatives with more drug-like properties. BZ194 (Fig. 4B) 
emerged as an antagonist of Ca2+ signalling in Jurkat T cells, blocking both the Ca2+ peak and plateau when 
co-injected with NAADP (Fig. 4C). Importantly, BZ194 co-injected with IP3 or cADPR did not inhibit Ca2+ 
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release, suggesting specificity for the NAADP pathway (Fig. 4D) [48]. Synthesis of BZ194 and related 
compounds is a high yielding two-step process that permits rapid preparation and evaluation of analogues, 
and this seems promising for future optimization. 
The utility of BZ194 as an NAADP antagonist was recently illustrated in vivo in a model of multiple sclerosis 
[49]. Interference with the NAADP signalling pathway suppresses the formation of autoimmune 
inflammatory lesions and thus might qualify as a novel strategy for the treatment of T-cell mediated 
autoimmune diseases. Moreover, the compound was also effective in cardiac myocytes in vitro and 
isoproterenol-induced arrhythmias in vivo were ameliorated by prior injection of BZ194 (Fig. 4E) [50].   
Conclusion 
Unravelling the mechanism by which a second messenger modulates its biological target is critical to 
understanding and ultimately intervening in Ca2+ signalling-related disease states. Although significant 
barriers must be overcome, synthetic chemistry can access functional molecules that modulate intracellular 
Ca2+ signalling both as mechanistic probes and prototype drug candidates. Strategies that combine rational 
design with chemical synthesis are best placed to deliver these powerful tools.  
Chemical approaches have tended toward one of two extremes. Complex analogues that are structurally 
very similar to the natural ligand may be synthetically challenging, requiring multi-step routes that may only 
afford small amounts of valuable material for biological evaluation. However, the close similarity of such 
analogues to their natural counterparts can lead to biologically relevant binding models while co-
crystallization with protein targets may provide invaluable structural and mechanistic insights. Another 
attraction of this approach, particularly for the mainstream organic chemist, is the opportunity to develop 
new synthetic chemistry during the design process. This can be expensive both in terms of time and quantity, 
meaning that subsequent scale-up to amounts needed for e.g. in vivo work is often difficult. However, in 
fortuitous instances work may lead both to independent novel chemistry and novel biology.  
On the other hand, an approach using short routes to simple, active compounds can also be very attractive. 
Such routes may lack chemical elegance per se, but permit rapid generation of analogues for evaluation. 
Retention of specificity is critical to the utility of this strategy. The biphenyl polyphosphates, for example, 
can be easily synthesized and retain surprisingly diverse activities at their target receptor or enzyme; 
although in these prototypes, membrane permeability and selectivity is compromised. While initially 
synthetically simple, the real challenge here lies in the medicinal chemistry design and optimization 
processes to tailor-make the desired biological effects. 
Drug-like properties are crucial for translation into early disease models. The first neutral cADPR analogues 
required a non-trivial synthesis but are new leads for simplified, membrane permeant modulators of Ca2+ 
release at the RyR. They suggest that activity can be retained when a phosphate or pyrophosphate is 
replaced with a bioisostere. By contrast, rational design of simple small analogues of nicotinic acid has 
afforded specific  antagonists for the NAADP receptor that are stable, membrane permeant and amenable 
to very straightforward chemistry, with the potential for later scale-up. BZ194 thus fulfils many 
considerations for an ideal design-based probe and its activity in disease models in vivo illustrates the 
promise of such an approach in generating drug-like analogues for second messenger signalling pathways. 
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Figures 
 
Figure 1: Agonists and antagonists of the IP3R 
(A) The structure of IP3 and AdA, SAR observations from synthetic AdA analogues; (B) Development of a 
rationale for the binding of the two ligands to the IP3R activating channel opening; requirement for both the 
- and -domains to be engaged; adapted from [21] (C) Proposed model in which adenine has a cation- 
interaction with Arg504 in the IP3R binding site, adapted from [19]; (D) 2-O-modifed ligands such as 2-O-
linked dimeric IP3 are partial agonists of the IP3R; (E) Simple benzene polyphosphates can be both antagonists 
and agonists of the IP3R, adapted from [27]; (F) Co-crystal structure of SHIP2 generated with lipid headgroup 
surrogate 2,3′,4,5′,6-pentakisphosphate (PDB code 4A9C) [28]. 
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Figure 2: Analogues of cADPR 
(A) Structure of cADPR, cIDPR and 8-Br-cIDPR, and new synthetic analogues; (B) cIDPR releases Ca2+ with 
equivalent potency to cADPR in permeabilized T-cells, adapted from [32]; (C) 8-Br-cIDPR is a membrane 
permeant agonist in whole T-cells, adapted from [33]; (D) 8-NH2-N9-butyl-cIDPR co-crystallized with CD38 
(PDB code 4TMF) [39]; (E) A neutral triazole-based cADPR analogue releases Ca2+ in sea urchin egg 
homogenate, adapted from [40]. 
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Figure 3: Exploring the SAR of ADPR at the TRPM2 cation channel 
(A) Synthetic analogues generate the first SAR for ADPR at the TRPM2 channel, adapted from [44]; (B) ADPR 
analogues were studied by whole cell patch-clamp experiments to measure Ca2+ and K+ ion flow; (C) 8-
Phenyl-ADPR is a potent antagonist (IC50 = 11 M) of ADPR (100M) induced Ca2+ influx at TRMP2; (D) 
Mobility of neutrophils, previously shown to be a downstream effect of TRPM2 activation, is (ii) reduced by 
TRPM2 antagonist 8-phenyl-ADPR compared to (i) control; adapted from [44]. 
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Figure 4: Design and activity of NAADP-receptor antagonist BZ194 
(A) The structure of NAADP and NADP highlighting nicotinic acid/nicotinamide switch; B) Small molecule 
NAADP antagonist BZ194; c) Effect of BZ194 on NAADP-induced Ca2+ signalling, adapted from [48]; D) BZ194 
is a selective antagonist for NAADP-mediated Ca2+ release [48]; E) Pre-injection of BZ194 ameliorates induced 
arrhythmia in vivo, adapted from [50]. Iso = β-adrenergic agonist isoproterenol. 
